Clinical Trial

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The objective of this randomized controlled clinical trial is to evaluate the efficacy of ctDNA-guided rechallenge with cetuximab plus trifluridine/tipiracil compared with bevacizumab plus trifluridine/tipiracil in patients with treatment-refractory, RAS/BRAF wild-type metastatic colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-02.
Trial Details
NCT Number NCT07012954
Lead Sponsor Sun Yat-sen University
Conditions Colorectal Cancer Metastatic
Enrollment 64 participants
Start Date 2025-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-24